These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1233 related articles for article (PubMed ID: 19509327)
21. Abatacept in biologic-naïve patients and TNF inadequate responders: clinical data in focus. Sherrer Y Curr Med Res Opin; 2008 Aug; 24(8):2283-94. PubMed ID: 18590608 [TBL] [Abstract][Full Text] [Related]
22. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis. Chan CY; Browning JC; Larsen F; Hsu S Dermatol Online J; 2008 Sep; 14(9):12. PubMed ID: 19061594 [TBL] [Abstract][Full Text] [Related]
23. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials. Lee YH; Bae SC Int J Rheum Dis; 2016 Nov; 19(11):1103-1111. PubMed ID: 26692536 [TBL] [Abstract][Full Text] [Related]
24. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response. Gibbons LJ; Hyrich KL BioDrugs; 2009; 23(2):111-24. PubMed ID: 19489652 [TBL] [Abstract][Full Text] [Related]
31. T-cell agents in the treatment of rheumatoid arthritis. Solomon GE Bull NYU Hosp Jt Dis; 2010; 68(3):162-5. PubMed ID: 20969545 [TBL] [Abstract][Full Text] [Related]
32. The comparison of effects of biologic agents on rheumatoid arthritis damage progression is biased by period of enrollment: data from a systematic review and meta-analysis. Favalli EG; Pregnolato F; Biggioggero M; Meroni PL Semin Arthritis Rheum; 2014 Jun; 43(6):730-7. PubMed ID: 24332807 [TBL] [Abstract][Full Text] [Related]
33. Abatacept in the treatment of rheumatoid arthritis. Todd DJ; Costenbader KH; Weinblatt ME Int J Clin Pract; 2007 Mar; 61(3):494-500. PubMed ID: 17313619 [TBL] [Abstract][Full Text] [Related]
34. Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials. Gerlag DM; Tak PP Best Pract Res Clin Rheumatol; 2008 Apr; 22(2):311-23. PubMed ID: 18455687 [TBL] [Abstract][Full Text] [Related]
35. MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice. Sfriso P; Salaffi F; Montecucco CM; Bombardieri S; Todesco S Reumatismo; 2009; 61(2):132-9. PubMed ID: 19633800 [TBL] [Abstract][Full Text] [Related]
36. Infectious complications of biologic agents. Martin-Mola E; Balsa A Rheum Dis Clin North Am; 2009 Feb; 35(1):183-99. PubMed ID: 19481004 [TBL] [Abstract][Full Text] [Related]
37. Rheumatoid arthritis: beyond tumor necrosis factor-alpha antagonists, B cell depletion, and T cell blockade. Manadan AM; Block JA Am J Ther; 2008; 15(1):53-8. PubMed ID: 18223354 [TBL] [Abstract][Full Text] [Related]
38. The British Society for Rheumatology Biologics Register: 6 years on. Hyrich KL; Watson KD; Isenberg DA; Symmons DP; Rheumatology (Oxford); 2008 Oct; 47(10):1441-3. PubMed ID: 18596052 [No Abstract] [Full Text] [Related]
39. Use of biologic agents in pediatric psoriasis. Marji JS; Marcus R; Moennich J; Mackay-Wiggan J J Drugs Dermatol; 2010 Aug; 9(8):975-86. PubMed ID: 20684148 [TBL] [Abstract][Full Text] [Related]